Zelicapavir for RSV in infants and toddlers
Part of Infections clinical trials.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has tested positive for RSV using a standard test, and does not also have COVID-19 or flu.
- Your child’s RSV symptoms started within the last 3 days (72 hours).
- Your child is at least 28 days old and not older than 36 months (3 years).
- Your child does not have a weak immune system (except for IgA deficiency).
- Your child has not had major surgery in the past 6 weeks, and none is planned during the study.
- Your child is not taking medicines that weaken the immune system (other than steroids for 5 days or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
This study tests a medication called palivizumab to help protect certain children from severe RSV (a common respiratory virus). It is for infants and young children with a higher chance of getting very sick from RSV, such as premature babies or those with certain heart or lung conditions.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
This trial tests a new medicine called SIBP-A16 to help protect infants from RSV, a common virus that can cause serious breathing problems. It is for preterm and full-term infants under 1 year old who are entering their first RSV season.
This study tests how your body's immune system responds to a new respiratory syncytial virus (RSV) vaccine. RSV is a common virus that causes respiratory infections, especially in older adults. The vaccine may help protect you from RSV disease.
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.